Goodwin advised Neon Therapeutics on the deal Neon Therapeutics (“NTGN”), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, closed its public offering of 6,250,000 shares of common…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
